Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10%
of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by …

Simple Summary An analysis of the presence of mutations of 105 genes in appendiceal
cancers through the lens of the reviewed literature supports the view that in most of them, the …

Establishing a prognostic genetic signature closely related to the tumor immune
microenvironment (TIME) to predict clinical outcomes is necessary. Using the Gene …

Abstract Introduction Glioblastomas (GBMs) usually occur as a solitary lesion; however,
about 0.5–35% present with multiple lesions (M-GBM). The genetic landscape of GBMs …

Background Colorectal cancers (CRCs) with microsatellite instability-high (MSI-H) are
hypermutated tumors and are generally regarded as immunogenic. However, their …

Background With an ever-increasing focus on personalized medicine, all factors known to
affect treatment response need to be considered when defining optimal therapy for …

Background: Bevacizumab-based regimens are used as standard treatments for colorectal
cancer. Unfortunately, there are no established predictive markers for bevacizumab …

High expectations are placed upon anti-angiogenic compounds for metastatic colorectal
cancer (mCRC), the first malignancy for which such type of treatment has been approved …

Phosphatase and tensin homolog (Pten) antagonizes PI3K-Akt signaling; therefore, Pten
impairment causes tumorigenesis. However, the correlation between Pten deficiency and …

Background: Colorectal cancer (CRC) is one of the most commonly-diagnosed
malignancies throughout the world and the fourth-leading cause of cancer deaths globally …